http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
CHARACTERISTICS OF COLLISION DAMAGE MITIGATION BRAKING SYSTEM FOR PEDESTRIAN PROTECTI
S. OIKAWA,Y. MATSUI,T. SAKURAI 한국자동차공학회 2014 International journal of automotive technology Vol.15 No.7
The vehicle travel velocity at pedestrian contact is considered to be an important parameter that affects thecrash outcome. To reduce vehicle/pedestrian impact velocity, a collision damage mitigation braking system (CDMBS) usinga sensor for pedestrian protection could be an effective countermeasure. The first purpose of this study is to clarify the relationbetween vehicle travel velocity and pedestrian injury severity due to differences in pedestrians’ ages in actual traffic accidents. The accident analyses were performed using vehicle-pedestrian accident data in 2009 from the database of the Institute forTraffic Accident Research and Data Analysis (ITARDA) in Japan. The result revealed that the fatality risk became higher withthe increase in vehicle travel velocity. The second purpose of this study is to determine the safety performance of productionvehicles equipped with the CDMBS for pedestrian protection. It was found that the CDMBS was highly effective in reducingthe impact velocity from 50 km/h (vehicle travel velocity) to below 17 km/h, that could result in a significant decrease infatality risk to be 2% or less. Additionally, the authors investigated a detectable zone with respect to a pedestrian’s positionin relation to the vehicle. It was shown that the detectable zones for production vehicles tested were limited to be inside thevehicle front width
Search for dark matter WIMPs using upward through-going muons in Super-Kamiokande
Desai, S.,Ashie, Y.,Fukuda, S.,Fukuda, Y.,Ishihara, K.,Itow, Y.,Koshio, Y.,Minamino, A.,Miura, M.,Moriyama, S.,Nakahata, M.,Namba, T.,Nambu, R.,Obayashi, Y.,Sakurai, N.,Shiozawa, M.,Suzuki, Y.,Takeuch American Physical Society 2004 PHYSICAL REVIEW D - Vol.70 No.8
Invariant Mass Spectroscopy for the Neutron Rich Nuclei
사토,추경호,방형찬,S. H. Choi,T. Nakamura,Y. Kondo,Y. Nakayama,N. Kobayashi,K. N. Tanaka,S. Deguchi,Y. Kawada,N. Tanaka,T. Sugimoto,T. Motobayashi,H. Sakurai,H. Otsu,N. Aoi,Y. Yanagisawa,S. Takeuchi,N. Fukuda 한국물리학회 2011 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.59 No.23
The neutron-rich carbon isotopes ^(19,17)C and a boron isotope ^(14)B are investigated respectively via proton inelastic and charge-exchange reactions on a liquid hydrogen target at around 70 MeV/nucleon at RIKEN. The invariant mass method in inverse kinematics involving coincidence detection of a charged fragment and a neutron both emitted at forward angles is employed to map the energy spectrum above the neutron decay threshold. Several resonance structures are revealed in the invariant mass spectra, and the nature for some of them is discussed from comparisons of differential cross section data with predictions of microscopic DWBA calculations based on spsdpf shell model wave functions and a recent parametrization of semi-microscopic nucleon-nucleus optical model potential (JLMB). By extrapolating the (p,n) cross sections leading to the 1^+ state at 1.27 MeV in ^(141)B to zero momentum transfer the Gamow-Teller transition strength is deduced. The value is found to compare well with that reported in a β-delayed neutron emission study.
β-delayedγ-ray spectroscopy of non-yrast states inTe138near the neutron drip line
Lee, P.,Moon, C.-B.,Lee, C. S.,Odahara, A.,Lozeva, R.,Yagi, A.,Nishimura, S.,Doornenbal, P.,Lorusso, G.,Sö,derströ,m, P.-A.,Sumikama, T.,Watanabe, H.,Isobe, T.,Baba, H.,Sakurai, H.,Browne, F. American Physical Society 2015 PHYSICAL REVIEW C - Vol.92 No.4
Charge neutralization of submicron aerosols using surface-discharge microplasma
Kwon, S.B.,Sakurai, H.,Seto, T.,Kim, Y.J. Elsevier 2006 Journal of aerosol science Vol.37 No.4
<P><B>Abstract</B></P><P>In this study we investigated the charging characteristics of a novel aerosol neutralizer (Surface-discharge Microplasma Aerosol Charger; SMAC) based on the dielectric barrier discharging. The surface discharge was induced by supplying positive and negative DC pulses with a pair of micro-structured electrodes. We confirmed the occurrence of the surface discharge by measuring the microdischarge current, and evaluated the charging performance of the SMAC as a particle neutralizer by measuring the penetration efficiency, neutralizing probability, and charge distribution for particles in the size range of 10–200nm. The SMAC was found to obtain a particle penetration exceeding 90% for the whole particle size range. The neutral fraction obtained by the SMAC showed good agreement with a bipolar diffusion charging theory and the fraction obtained by an <SUP>241</SUP>Am radioactive source when the SMAC was optimized for aerosol neutralization with the offset voltage control. The charge distributions of negatively and positively charged particles by the SMAC and the <SUP>241</SUP>Am neutralizer were in good agreement also. The charge balance of positive and negative particles obtained by the SMAC was effectively controlled by adjusting the offset voltage on each electrode. This is the first study to demonstrate the successful use of dielectric barrier surface discharge to bring particles of 10–200nm to an equilibrium charging state in a controllable manner.</P>
T. Sakurai,K. Fujimoto,S. Okubo,H. Ohta,Y. Uwatoko 한국자기학회 2013 Journal of Magnetics Vol.18 No.2
We have developed a high-field and high-frequency ESR system using a commercially available magnetometer equipped with the superconducting quantum interference device (SQUID). This is magnetization detection type ESR and ESR is observed as a change of the magnetization at the resonance condition under irradiation of the electromagnetic wave. The frequency range is from 70 to 315 GHz and the maximum magnetic field is 5 T. The sensitivity is estimated to be 10<SUP>13</SUP> spins/G. The advantage of this system is that the high-field ESR measurements can be made very easily and quantitatively. Moreover, this high-field ESR can be applied to the measurements under pressure by using a widely used piston-cylinder pressure cell.
Selection of Particle Beam vs. Photon Beam Radiation Therapy for HCC: Japanese Experience
( Hideyuki Sakurai ),( M Iizumi ),( S Shimizu ),( H. Numajiri ),( M. Mizumoto ),( K. Nakai ),( T. Okumura ) 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Radiation therapy (RT) using conventional fractionation has not been thought to be curative enough for hepatocellular carcinoma (HCC) and it has not been performed as a high priority in comparison to other standard treatments, such as surgery, percutaneous ablation and transcatheter approach. Because the liver is high sensitive to radiation, especially for patients with liver cirrhosis, non-irradiated normal liver volume must be preserved as much as possible when curative radiation is given for HCC. Since many technological progress has been made in radiation oncology in recent years, RTs are used as an important curative treatment option for liver cancer. Stereotactic body radiotherapy (SBRT), which is included in Japanese national health insurance system, is a technique to accurately concentrate doses three-dimensionally on the target with short-term irradiation of 1-2 weeks. This technique can be used for relatively small tumors less than 5 cm with about 90% local control. Recently, Hara K. et al. reported survival result of SBRT comparing radiofrequency ablation using propensity score analysis, and they concluded that SBRT appears to be an acceptable alternative treatment option for patients who are not candidates for RFA. In addition, in Japan, muticenter prospective study of SBRT for untreated solitary primary HCC, so called STRSPH study, is ongoing. Eligible patients are untreated solitary, Child-Pugh score ≦7, Diameter: 1-5cm, UICC 7th. T1, T2, T3bN0M0, performance status score of 0-2, and 20-85 year-old. The primary endpoint / number of cases of this study are 3-year overall survival / 60 cases. Particle beam therapy (PBT: proton beam therapy, heavy ion beam therapy) has unique character of radiation dose distribution, which is called Bragg peak. PBT can accumulate more dose to the target with minimizing normal liver dose. Primary liver tumor is an important indication that has been specified to be of the highest priority by the American Society for Radiology and Oncology (ASTRO). In fact, most of the studies on PBT for HCC are published by Japan, and rather highly evaluated abroad. Eighteen proton facilities and 6 heavy ion facilities are working now in Japan. The local control rate was approximately 90% and the 5-year survival rate was reported to be approximately 50%. According to the results of our hospital, PBT can control 90% of a large tumor of 10 cm or more. Clinical studies of PBT report favorable therapeutic effects, even for not only large tumors but also tumors in elderly patient. In addition, PBT has been clearly shown to play an important role in the treatment of HCC-related portal vein tumor thrombosis (PVTT). When applied as a curative treatment for bulky tumors with portal vein embolism, median survival time of 27 months has been obtained in our study. The clinical study comparing proton vs surgery, which is non-randomized trial using propensity score, is ongoing in Japan (JCOG1315C). Japanese Society for Radiation Oncology (JASTRO) defined identical rule for indication and treatment method in PBT for HCC, and the all data should be registered in the data-base since 2016. We are facing an aging society, although there are indications of surgery and other local treatment, the number of patients who choose curative radiation therapy due to aging and co-existing disease is increasing. But, the history of radical RT for HCC is still short, and sufficient consensus has not been obtained regarding the criteria for its therapeutic indication. RT may become an option for curative local treatment of HCC, but no specific role for RT has been described in the Japanese treatment guidelines. In the future, it is important to proceed with research to clarify the indication of curative radiation therapy, keeping in mind the comparison with other therapies.